Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: Neuromodulation. 2020 Sep 17;24(5):870–878. doi: 10.1111/ner.13256

Figure 3.

Figure 3.

Scatterplots reflecting the relationship between changes in anger from baseline to end-of-treatment (at endpoint of unblinded phase) and changes in PTSD symptoms (A), depressive symptoms (B), and sleep quality (C), as well as between changes in PTSD symptoms baseline to end-of-treatment improvements and changes in sleep quality (D) for those who received four or two weeks of iTBS.